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Abstract
Background: Dabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-
optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore
affect the cost-effectiveness of dabigatran compared with warfain. We examined the cost-effectiveness of dabigatran versus
warfarin therapy with genotype-guided management in patients with atrial fibrillation (AF).
Methodology/Principal Findings: A Markov model was designed to compare life-long economic and treatment outcomes
of dabigatran (110 mg and 150 mg twice daily), warfarin usual anticoagulation care (usual AC) with mean TTR 64%, and
genotype-guided anticoagulation care (genotype-guided AC) in a hypothetical cohort of AF patients aged 65 years old with
CHADS2 score 2. Model inputs were derived from literature. The genotype-guided AC was assumed to achieve TTR=78.9%,
adopting the reported TTR achieved by warfarin service with good anticoagulation control in literature. Outcome measure
was incremental cost per quality-adjusted life-year (QALY) gained (ICER) from perspective of healthcare payers. In base-case
analysis, dabigatran 150 mg gained higher QALYs than genotype-guided AC (10.065QALYs versus 9.554QALYs) at higher
cost (USD92,684 versus USD85,627) with ICER=USD13,810. Dabigatran 110 mg and usual AC gained less QALYs but cost
more than dabigatran 150 mg and genotype-guided AC, respectively. ICER of dabigatran 150 mg versus genotype-guided
AC would be .USD50,000 (and genotype-guided AC would be most cost-effective) when TTR in genotype-guided AC was
.77% and utility value of warfarin was the same or higher than that of dabigatran.
Conclusions/Significance: The likelihood of genotype-guided anticoagulation service to be accepted as cost-effective
would increase if the quality of life on warfarin and dabigatran therapy are compatible and genotype-guided service
achieves high TTR (.77%).
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Introduction
Warfarin was shown to effectively reduce risk of ischemic
stroke in patients with atrial fibrillation (AF) [1]. The
anticoagulation effect of warfarin, measured by the international
normalized ratio (INR), is subject to wide inter- and intra-
individual variability that possibly leads to hemorrhagic events
despite careful dosage titration [2]. There is continuing search
of new anticoagulants for safe and effective stroke prevention in
patients with AF. Recently, results of the Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY), a
multi-centered trial including over 18,000 patients with AF,
demonstrated that dabigatran (an oral direct thrombin inhibitor)
110 mg twice daily was associated with lower major bleeding
and similar effectiveness in stroke prevention when compared
with warfarin [3]. At higher dose (150 mg twice daily),
dabigatran was associated with lower rate of stroke and similar
major bleeding rate comparing to warfarin. Dabigatran at both
doses were associated with higher risk of myocardial infarction
and dyspepsia. An analysis of the RE-LY data showed a trend
of better relative performance for dabigatran in centers with
lower mean patient-time in therapeutic range (TTR), despite the
differences in stroke and intracranial bleeding among centers in
different TTR quartiles were not statistically significant [4].
Dabigatran 150 mg (twice daily) was more cost-effective than
dabigatran 110 mg or warfarin therapy [5] unless the TTR with
warfarin was .72.6% [6].
Warfarin therapy with good INR control (TTR.75%) is
associated with lower event rates, yet the majority of patients on
warfarin achieve only suboptimal INR control [1]. Association of
warfarin pharmacogenetics (CYP2C9 and VKORC1genotypes) and
dosage requirement was widely examined. Nevertheless, genotype-
guided warfarin dosing algorithm alone did not achieve significant
improvement in TTR at centers with high level of anticoagulation
control [7]. Genotype-guided warfarin dosing was potentially cost-
effective in practice sites with poor INR control or patients with
high risk of bleeding [8–9]. Further clinical research demonstrated
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managed the warfarin therapy was associated with reduction in
hospitalization for major bleeding and thromboembolism [10].
Applying genotype data in both warfarin dosing and patient care
therefore might optimize INR control.
Strategies to achieve good INR control (TTR.75%) with
warfarin and using a direct thrombin inhibitor (dabigatran) have
different economic and clinical implications for patients, clinicians
and decision-makers to consider. The objectives of the present
study were to evaluate the potential clinical and economic
outcomes of genotype-guided management of warfarin and use
of dabigatran in patients newly diagnosed with AF from the
perspective of healthcare payers.
Methods
Decision Model
A Markov model (Figure 1) was designed to simulate the life-
long outcomes of four anticoagulation treatment strategies in a
hypothetical cohort of 65-year-old patients with newly diagnosed
AF: (1) Standard warfarin dosing with usual anticoagulation care
(usual AC), (2) genotype-guided warfarin dosing and manage-
ment (genotype-guided AC), (3) initiation of dabigatran 110 mg
twice daily, and (4) initiation of dabigatran 150 mg twice daily.
Markov modeling is a form of decision analysis in which
hypothetical patients proceed through health states over time
based on probability inputs of the model. Patients of all
treatment arms entered the model at the Markov health state
of being well and transited to other health states (remained well,
dyspepsia, myocardial infarction, ischemic stroke with major
deficit, minor deficit or no residual deficit, intracranial hemor-
rhage, extra-cranial hemorrhage and dead) in the next cycle.
Two tiers of outcomes were simulated for each study arm: Total
direct medical cost and quality-adjusted life-years (QALYs)
gained were calculated over a maximum period of 25 years
with monthly cycle.
The patient selection criteria were adopted from those of the
RE-LY trial [3]. Patients aged 65 years or above with a high
risk for stroke (CHADS2 score of 2 or higher) were included.
Exclusion criteria included presence of severe heart-valve
disorders or severe stroke within 6 months. The warfarin dose
in usual AC group would be adjusted to an INR of 2–3, and
the INR would be monitored at least monthly thereafter. In the
genotype-guided AC group, CYP2C9 and VKORC1 genotypes
would be examined by in-house genotyping assay. The starting
dose of warfarin would be designed by a dosing algorithm,
using demographic, clinical and genetic (CYP2C9 and VKORC1
genotypes) data to target at INR 2–3 [11]. Patients with wild-
type CYP2C9 and VKORC1 (normal warfarin sensitivity) would
be followed up by usual anticoagulation care (at least monthly
INR monitoring), whereas patients with genotypes of high or
low warfarin sensitivity would be managed by intensified
anticoagulation care (INR monitoring at least twice per month
and patient education on warfarin therapy including impact of
patient’s genotype on warfarin sensitivity and INR control). The
INR control might be in, below or above the target range and
patients might consequently experience bleeding or ischemic
events. In dabigatran 110 mg and 150 mg groups, patients
would be initiated with dabigatran 110 mg twice daily and
150 mg twice daily, respectively. Patients who survived ischemic
stroke would change the initial anticoagulation therapy to
dabigatran 150 mg twice daily. Those who survived major
bleeding event would stop the current anticoagulation therapy
and start on aspirin alone.
Clinical Inputs
The clinical inputs of the model were retrieved from literature.
Literature search on MEDLINE over the period 1990–2012 was
performed using keywords ‘‘atrial fibrillation’’, ‘‘warfarin’’,
‘‘dabigatran’’, ‘‘bleeding’’, ‘‘thromboembolism’’, ‘‘QALY’’,
‘‘INR’’, ‘‘genotyping’’, ‘‘VKORC1’’ and ‘‘CYP2C9’’. The selection
criteria of clinical trials on warfarin and dabigatran treatment and
related events were: (1) reports in English; (2) patients involved in
the trials were at least 18 years of age; and (3) control of INR and/
or the incidence of major events (bleeding or ischemic event) were
reported. All articles retrieved by this process were screened for
relevance to our model. Case reports were excluded. The
preferred type of studies was meta-analysis. If multiple randomized
controlled trials were available for the same model input, the
pooled average would be derived from the studies weighted against
the number of patients in each study and used as the base-case
model input. If a model input was reported in both randomized
and non-randomized trials, the pooled average from randomized
trials would be used as base-case value whereas the range for
sensitivity analysis would be derived from both randomized and
non-randomized trials. If a model input was not reported in meta-
analyses nor randomized controlled trials, it would be estimated
from the findings of non-randomized controlled trials.
Clinical inputs were shown in Table 1. The mean TTR (64%)
in warfarin group of the RE-LY trial [3] was used as the base-case
TTR of patients in usual AC. Out-of-range INR was defined as
,1.8 or .3.2. The prevalence of patients with normal warfarin
sensitivity was retrieved from a prospective study [10]. In the RE-
LY trial, the anticoagulation control at the study centers were
stratified in four quartiles (TTR ,57.1%, 57.1%–65.5%, 65.5%–
72.6% and .72.6%) [4]. In those centers achieving good
anticoagulation control (TTR.75%), the median TTR was
78.9% with inter-quartile range of 70.9%–86.7%. The genotype-
guided AC was assumed to achieve good anticoagulation control
with base-case TTR=78.9%. The range for sensitivity analysis
was extended to 65%–100% in order to examine the level of TTR
required for genotype-guided AC to be cost-effective.
The rates of major bleeding (including intracranial and
extracranial hemorrhage) and ischemic stroke in therapeutic range
of INR (INR # 3 and INR $ 2) and the risks for stroke in under-
coagulated patients (INR ,2) and major bleeding in over-
coagulated patients (INR.3) were estimated in a meta-analysis
of outcomes of warfarin anticoagulation for atrial fibrillation [12].
The risk of major bleeding in under-coagulated patients and major
thromboembolic events in over-coagulated patients were both
assumed to be the same as patients with in-range INRs.
The relative risks of major bleeding and ischemic event and
rates of myocardial infarction of dabigatran groups, comparing to
usual AC were derived from the results of RE-LY [3]. The rates of
major bleeding and ischemic events in dabigatran arms were
estimated from the relative risk of event of dabigatran versus usual
AC, and the rate of major events in usual AC. The rate of ischemic
stroke and percentage of ischemic strokes with major, minor or no
deficit on aspirin were derived from prospective trials [3,13–15].
The rate of major bleeding on aspirin was estimated from relative
risk of bleeding on aspirin versus warfarin and the bleeding rate in
usual AC [16–17]. The mortality rates of intracranial hemorrhage,
extracranial hemorrhage, ischemic stroke and acute myocardial
infarction within 30 days of event were estimated from observa-
tional studies [15,18–19].
Utility and Cost Inputs
The QALYs gained in each study arm were estimated from the
utility scores of different health states (remained well on warfarin,
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neurologic deficit, mild neurologic deficit, no neurologic deficit,
extra-cranial hemorrhage and dead) and the time spent in each
state (Table 1) [20–24]. The QALYs were discounted with a rate
of 3% annually. The one-time treatment cost and monthly cost of
major events (extracranial hemorrhage, intracranial hemorrhage,
stroke and myocardial infarction) were estimated from the
perspective of healthcare payers [25–28]. The monthly cost of
usual anticoagulation care management, including staff time,
laboratory tests and administrative cost, was estimated from
economic analyses on anticoagulation care [29–30]. The cost of
the hypothetical intensified anticoagulation service was assumed to
be 2-fold (ranging 2- to 3-fold) of the usual anticoagulation service
cost. The monthly warfarin drug cost was estimated from retail
pricing of generic warfarin [31]. The cost of CYP2C9 and VKORC1
genotyping assay was estimated from literature [32]. The cost of
dabigatran was retrieved from retail pricing [31]. All costs were
discounted to 2012 costs with an annual rate of 3%.
Model Validation, Cost-effectiveness Analysis and
Sensitivity Analysis
In the present model, the rates of major bleeding and ischemic
stroke in the warfarin therapy arms were estimated from the
average individual TTR and the risk of event in patients with out-
of-range INR. The event rates in dabigatran groups were
simulated by relative risks of events in dabigatran versus warfarin.
The event rate of genotype-guided AC was estimated using
assumed improvement in TTR. The predictive validity of the
model in the above study arms was assessed by comparing the
model results with the clinical trial results.
A treatment strategy was dominated when it was more costly
and gained less QALYs than another treatment option. The
incremental cost per QALY gained (ICER) of each arm (excluding
the dominated strategy), comparing to the next less costly arm, was
calculated using the following equation: Dcost/DQALYs. Using
the threshold of USD50,000 as the willingness-to-pay per QALY,
the most effective strategy with ICER USD50,000 or less was
considered as cost-effective [33].
Sensitivity analysis was performed by TreeAge Pro 2009
(TreeAge Software, Inc., Williamstown, MA, USA) and Microsoft
Excel 2007 (Microsoft Corporation, Redmond, WA, USA) to
examine the robustness of the model results to variation of all
parameters. Threshold values of influential factors were identified
by one-way sensitivity analysis over the high/low values. To
evaluate the impact of the uncertainty in all variables simulta-
neously, a probabilistic sensitivity analysis was performed using
Monte Carlo simulation. The cost and QALYs of each study arm
were recalculated 10,000 times by simultaneously varying the
values of each model input through the ranges of sensitivity
analysis.
Results
Model Validation
The predictive validity of model was examined by comparing
the rates of major bleeding and ischemic stroke (per 100 patient
years) simulated by the model with the actual reported event rates
in RE-LY trial [3,34]. In the base-case scenario, patients in usual
Figure 1. Markov model.
doi:10.1371/journal.pone.0039640.g001
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Variables Base-case value Range References
INR control on Warfarin
Percentage of in-range time in usual AC 64% 57%–65.5% 3–4
Percentage of in-range time in genotype-guided AC 78.9% 65%–100% 4
Proportion of below-range time among out-of-range time 52% 42%–62% 1
Prevalence of patients with normal warfarin sensitivity 29.2% 23.4%–35.0% 10
Stroke
Rate of ischemic stroke: warfarin at in-range INR (per patient year) 1.3% 0.5%–1.6% 12
Relative risk of ischemic stroke: warfarin at below-range INR 1.70 1.70–6.88 12
Relative risk of ischemic stroke: warfarin at above-range INR 1 Assumption
Rate of ischemic stroke: aspirin (per patient year) 2.7% 0.8%–13.7% 14
Relative risk of stroke: dabigatran 150mg vs warfarin 0.76 0.59–0.97 3, 34
Relative risk of stroke: dabigatran 110mg vs warfarin 1.11 0.88–1.39 3, 34
Ischemic stroke on warfarin or dabigatran (%) 3,13,15
Fatal (within 30 days) 8.2% 8.2%–10.1%
Major deficit 40.2% 40.2%–41.7%
Minor deficit 42.5% 34.8%–42.5%
No residual deficit 9.1% 9.0%–13.3%
Ischemic stroke on aspirin (%) 3,13,15
Fatal (within 30 days) 17.9% 10.1–17.9
Major deficit 30% 30.0–41.7
Minor deficit 41% 34.8–41.0
No residual deficit 11% 11.0–13.3
Major Bleeding
Rate of major bleeding: warfarin at in-range INR (per patient year) 1.5% 1.0%–1.5% 12
Relative risk of major bleeding: warfarin at above-range INR 8.28 3.21–8.28 12
Relative risk of major bleeding occurred at below-range INR 1 – Assumption
Relative risk of major bleeding: aspirin vs warfarin 0.64 0.5–0.8 16–17
Relative risk of major bleeding: dabigatran 150mg vs warfarin 0.93 0.81–1.07 3, 34
Relative risk of major bleeding: dabigatran 110mg vs warfarin 0.80 0.70–0.93 3, 34
Proportion of ICH in major bleeding
Warfarin 22% 18%–25% 3–4
Dabigatran 150mg 12.6% 6.3%–13.4% 4
Dabigatran 110mg 8.9% 4.6%–11.9% 4
Aspirin 21% 16%–25% 16–17
Mortality rate of ICH 48.6% 36%–61% 18–19
Mortality rate of ECH 5.1% 0.1%–10.1% 18
MI
Rate of MI (per patient year)
Warfarin 0.64% 0.51%–0.77% 3,34
Aspirin 0.53% 0.40%–0.60% 39–40
Dabigatran 150mg 0.81% 0.65%–0.97% 3,34–35
Dabigatran 110mg 0.82% 0.66%–0.98% 3,34–35
Mortality rate of MI 15% 10.3–24.6% 41
Utility inputs
Warfarin therapy 0.95 0.95–1 20–22
Dabigatran therapy 1.00 0.95–1 Assumption,42
Aspirin
Major bleeding
Intracranial 0.51 0.15–0.85 20–22
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ischemic stroke (1.35%) rates, similar to those in RE-LY trial
(3.57% and 1.20% respectively). Comparing to the RE-LY
findings, the simulated bleeding rates of dabigatran 110 mg
(2.71% vs 2.87%) and dabigatran 150 mg (3.15% vs 3.32%) as
well as simulated ischemic stroke rates of dabigatran 110 mg
(1.51% vs 1.34%) and dabigatran 150 mg (1.03% vs 0.92%) were
compatible to the reported event rates. The genotype-guided AC
was hypothesized to achieve TTR 78.9% in the base-case scenario
and the total simulated event rate of genotype-guided AC
(bleeding 2.21% and ischemic stroke 1.27%) reduced by 26%
when compared to usual AC. It was similar to the reported
reduction in hospitalization rate (by 28%) for bleeding or
thromboembolism associated with providing patients’ warfarin
genotyping data with interpretations to clinicians in a prospective
study [10].
Table 2. Expected Cost and QALYs in Base-case Analysis.
Strategy Cost (USD) QALYs ICER
a (USD) vs genotype-guided AC
Genotype-guided AC
b 85,627 9.554 –
Usual AC 90,481 9.444 Dominated by genotype-guided AC
Dabigatran 150mg 92,684 10.065 13,810
Dabigatran 110mg 102,536 10.026 Dominated by dabigatran 150mg
a: The incremental cost per QALY gained (ICER) of each arm (excluding the dominated strategy), comparing to the next less costly arm, was calculated using the
following equation: Dcost/DQALYs. Using the threshold of USD50,000 as the willingness-to-pay per QALY, the most effective strategy with ICER USD50,000 or less was
considered as cost-effective.
b: AC=Anticoagulation care.
doi:10.1371/journal.pone.0039640.t002
Table 1. Cont.
Variables Base-case value Range References
Extracranial 0.80 0.79–0.84 21–22
Ischemic stroke
Major deficit 0.39 0–0.50 20–22
Minor deficit 0.75 0.50–0.99 20–22
Myocardial infarction 0.84 0.67–0.96 23
Dyspepsia 0.97 0.74–0.98 24
Cost inputs (USD)
Genotyping 72 50–200 32
Monthly cost of usual AC per patient 31 21–36 29–30
Increment factor of monthly cost of intensified AC 2 2–3 Assumption
Monthly cost of warfarin 6 4–20 31
Monthly cost of dabigatran 110mg twice daily 240 200–270 Assumption
Monthly cost of dabigatran 150mg twice daily 240 200–270 31
One-time cost of major event 25
ICH 45,959 21,675–55,151
ECH 23,798 17,445–39,308
Ischemic stroke
Moderate to severe 65,984 53,243–78,724
Mild 44,043 35,234–52,852
TIA 19,514 15,611–23,417
Myocardial infarction
Survived 27,996 20,945–43,727
Dead 20,654 14,447–44,498
Monthly cost 25–28
ICH 5,740 2,100–10,000
Ischemic stroke with major deficit 5,430 2,100–9,000
Ischemic stroke with mild deficit 2,500 1,000–4,300
ICH and ischemic stroke 7,280 3,180–13,790
doi:10.1371/journal.pone.0039640.t001
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The base-case analysis (Table 2) showed that both dabigatran
arms gained higher QALYs than warfarin arms with higher cost.
Dabigatran 110 mg gained less QALYs but cost more than
dabigatran 150 mg and therefore dabigatran 110 mg was
dominated by dabigatran 150 mg. Similarly, genotype-guided
AC dominated usual AC. After excluding the two dominated
options, the ICER of dabigatran 150 mg was USD13,810 when
compared with genotype-guided AC. Using the threshold of
USD50,000 as the willingness-to-pay per QALY, dabigatran
Figure 2. One-way sensitivity analysis on incremental cost per quality-adjusted life-year (ICER) gained by dabigatran 150mg.
doi:10.1371/journal.pone.0039640.g002
Figure 3. Two-way sensitivity analyses on the cost-effectiveness of dabigatran 150mg versus genotype-guided anticoagulation
care (AC).
doi:10.1371/journal.pone.0039640.g003
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scenario.
Five model inputs were shown to be influential to the ICER
of dabigratan 150 mg in one-way sensitivity analysis: (1) average
TTR in genotype-guided AC, (2) utility of warfarin, (3) utility of
dabigatran, (4) risk of stroke with dabigatran 150 mg versus
warfarin and (5) stroke rate with warfarin when INR was in
target range. Figure 2 showed the variation of ICER of
dabigatran 150 mg over the ranges of these five variables. The
ICER of dabigatran 150 mg would become .USD50,000 (and
genotype-guided AC would become the most cost-effective
option) when average TTR in genotype-guided AC was
extended over 98%, utility of warfarin therapy was $0.99, or
utility of dabigatran therapy was #0.95. The change of stroke
rate with warfarin or risk of stroke with dabigatran would vary
the ICER of dabigatran 150 mg from less than USD10,000 to
as high as USD38,000.
Two-way sensitive analyses (Figures 3a, b) were conducted to
further examine the impact of variation of warfarin utility versus
TTR in genotype-guided AC, and warfarin utility versus
dabigatran utility on the model results. The results (Figure 3a)
indicated that, with utility of warfarin ranging between 0.95 to 1.0,
genotype-guided AC would be the most cost-effective option if it
achieved high TTR (77% to 98%). Figure 3b showed that the
genotype-guided AC would be the most cost-effective option if
utility value of warfarin is the same or higher than that of
dabigatran.
The probabilistic sensitivity analysis was performed by 10,000
Monte Carlo simulations. The probabilities of each strategy to
be cost-effective were examined in the acceptability curve over a
wide range of willingness-to-pay per QALY, from USD0-
150,000 (Figure 4). Using USD50,000 as the threshold
willingness-to-pay, dabigratan 150 mg was the most likely
option to be cost-effective in 51.6% of time, whereas
genotype-guided AC was cost-effective in 46.2% of time. The
probabilities of usual AC and dabigatran 110 mg to be cost-
effective were 0.6% and 1.6% of time, respectively. Dabigatran
150 mg was more costly (p,0.001) than genotype-guided AC
with mean cost difference of USD10,416 (95%CI=10,282–
10,550) and gained higher QALYs (p,0.001) by mean QALYs
difference=0.217 (95%CI=0.214–0.220).
Discussion
Dabigatran 150 mg twice daily regimen was associated with
lower rates of stroke for patients with AF, but similar rate of major
bleeding comparing with warfarin therapy controlled at average
TTR of 64% in the RE-LY trial. Recent meta-analysis has
demonstrated that dabigatran is associated with increased risk of
myocardial infarction [35]. Dabigatran may offer patients an
option with less stringent monitoring requirements than warfar-
in therapy. Nevertheless, the high drug cost of dabigatran
(approximately USD240 per month) would make it less affordable
as life-long treatment for many patients. The choice of an
anticoagulation service striving to achieve high TTR with warfarin
therapy, or using oral direct thrombin inhibitor require qualifying
and quantifying the impact of stroke prevention, risk of bleeding
and acute coronary events.
In the present study, we assessed the potential life-long cost and
effectiveness of applying pharmacogenetic data to guide the dosing
and management of warfarin versus using two dabigatran
regimens for newly diagnosed AF patients. In base-case analysis,
dabigatran 150 mg was the preferred option with ICER
(USD13,810) less than the threshold of willingness-to-pay per
QALY (USD50,000). Our base-case results were consistent with
the cost-effectiveness analyses comparing dabigatran with warfarin
in the US and Canada settings [5,36].
In the one-way sensitivity analysis, the variation of three
variables increased the ICER of dabigatran 150 mg over
USD50,000: TTR in genotype-guided AC and utility values of
warfarin and dabigatran. Our findings showed that a slight
variation of the utility values of the two drugs between 0.95 to 1.0
could change the choice of the most cost-effective option from
Figure 4. Variation in probability of each treatment option to be cost-effective against willingness-to-pay per QALY.
doi:10.1371/journal.pone.0039640.g004
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dabigatran, requiring less periodic blood testing and follow-ups,
would have better quality of life (thus higher utility value) than
warfarin therapy. The base-case utility value selected for
dabigatran (1.0) was therefore higher than that of warfarin
(0.95). Freeman et al reported the results of a cost-effectiveness
analysis of dabigatran versus usual warfarin care that dabigatran
was more cost-effective (ICER=USD45,372) when the base-case
utility score of dabigatran was higher than that of warfarin (0.994
versus 0.987) [5]. These findings were consistent with results of our
base-case analysis. Freeman et al also found the cost-effectiveness
of dabigatran sensitive to the variation of utility values of the
anticoagulants over a narrow range (0.95 to 1.0) in a similar
manner to our two-way sensitivity analysis.
The 10,000 Monte Carlo simulations showed that the difference
in QALYs between dabigatran 150 mg and genotype-guided AC
was very narrow (0.217 QALYs =2.6 quality-adjusted months),
implying that the life-long impact of stroke prevention and adverse
events of both arms were compatible. The probabilities of
dabigatran 150 mg and genotype-guided AC to be cost-effective
were very similar (approximately 50%), possibly due to the impact
on ICER as a result of small variation in utility values of the two
drugs. In order to be better informed on the impact of patient
quality of life while receiving different anticoagulants, health-
related quality of life research comparing dabigatran versus
warfarin is highly warranted.
We also explored the potential improvement in INR control
required in order for genotype-guided AC to be cost-effective. The
two-way sensitivity analysis showed that at high utility value of
warfarin therapy (.0.98), genotype-guided AC would need to
improve TTR from 64% in usual AC to .77% to become the
most cost-effective option. Our results were similar to the cost-
effectiveness findings reported by Shah and Gage that warfarin
therapy would be more cost-effective than dabigatran when the
average TTR was over 72.6% and the utility values of warfarin
was high (0.987) [6].
The clinical benefits of warfarin pharmacogenetics remain
uncertain. Most genotype-guided dosing algorithms only explain
up to 46%–68% of dosage variation [11,37]. It is also
anticipated that impact of genotype-based dosage initiation on
INR control would not be a long-term effect. Any long-term
benefit of applying pharmacogenetics data should be generated
from genotype-based triage of patients to intensified anticoag-
ulation care. Epstein et al. reported findings of a prospective,
comparative study that providing CYP2C9 and VKORC1
genotyping results with interpretation to physicians who
managed warfarin therapy would reduce the hospitalization
rate for bleeding or thrombembolism by 28%, when comparing
to historical records [10]. The reduction in hospitalization was
believed to be a combined effect of warfarin dosage adjustment
and more vigilant care for warfarin-sensitive patients, yet the
results was limited by the study design. Randomized controlled
trials are required to investigate the benefits of applying
pharmacogenetics to guide both dosing and care model of
warfarin therapy. Possible interventions to apply genotype data
to improve anticoagulation control include incorporating the
knowledge of patients’ genotype in dosing, monitoring and
patient education. Patients with low-dose genotype could be
triaged to an intensive anticoagulation service with more
frequent monitoring and in-depth patient education to empha-
size the effect of genetic make-up on warfarin therapy [38].
This study is an example of decision analysis to compare the
potential changes in economic and clinical outcomes of a
dabigatran versus warfarin therapy with interventions to upgrade
INR control. The results demonstrated a few influential factors
(utility values of the two drugs and INR control required by
genotype-guided AC to be cost-effective) which indicated the
target values for dabigatran 150 mg or genotype-guided AC to be
cost-effective, and therefore assisted clinicians to be better
informed on the choice of anticoagulation therapy.
The present model was limited by projecting life-long events
using key model inputs of dabigatran from a clinical trial of 2
years. Projecting life-long outcomes using short-term clinical trial
data may weaken the robustness of the model findings. The cost
items were limited to the resources of anticoagulation therapy and
related complications. All the model inputs were examined in
sensitivity analysis and probabilistic sensitivity analysis over a wide
range to test for robustness of the results.
In conclusion, dabigatran 150 mg seems to be cost-effective
(ICER ,USD50,000) at centers with TTR #64%. The better
INR control (measured by TTR) achieved by an anticoagulation
center, the less cost-effective of dabigatran would become. The
likelihood of genotype-guided anticoagulation service to be
accepted as cost-effective would increase if the quality of life on
warfarin and dabigatran therapy are compatible and genotype-
guided service achieves high TTR (.77%). Further work is
needed to better compare clinical outcomes and quality of life on
dabigatran and genotype-guided warfarin management.
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